The first of 1,100 patients has been enrolled on a new cancer trial for treatment for men with high risk, clinically localised prostate cancer.
The DASL-HiCaP Trial, led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), enrolled its first patient at Chris O’Brien Lifehouse in Camperdown in Sydney this week.
Prostate cancer remains the most common cancer in Australian men and the leading cause of cancer related-mortality for men in developed countries.
The new randomised phase 3 study aims to demonstrate that the addition of the new potent oral hormonal therapy, darolutamide, to the standard radiation therapy and testosterone suppression improves the outcomes of men with localised high-risk prostate cancer.
Study Principle Investigator and medical oncologist Professor Lisa Horvath is excited by the potential this trial has for patients.
“The patients in this study will have advanced, metastatic prostate cancer combined with a high PSA score, meaning that their cancer is aggressive. To date there have been few treatment options available for this group. This trial holds the promise of improved survival for these men,” said Prof Horvath.
Outcomes of the trial will be measured in terms of whether the addition of darolutamide decreases the risk of spreads of prostate cancer to other parts of the body as well as improving quality of life and potentially decrease the risk of prostate cancer death.
“We know clinical trials are the only way to find out the safety and effectiveness of new treatments and whether they should become the new gold standard for treatment in the future,” said ANZUP Chair, Professor Ian Davis.
The first patient enrolled marks the start of the journey to recruit and follow up 1,100 eligible patients across over 100 cancer centres across Australia, New Zealand, US, Canada, Europe and Ireland.